Solomon et al say that several biological pathways could underlie a potential association between selective COX-2 inhibitors and coronary events. For example, in rat models of hypertension, celecoxib ...
December 14, 2010 (New Haven, Connecticut) — Additional research confirms that the doubling of cardiovascular risk associated with the now-discontinued COX-2 inhibitor rofecoxib (Vioxx, Merck) ...
A comparison of internal company documents, data submitted by the company to the FDA, and published clinical trial results indicates that the risk-benefit profile of rofecoxib in clinical trials ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio In 2001, Steve Nissen, MD, and Eric Topol ...
Merck & Co. announced Sept. 30 a voluntary worldwide withdrawal of rofecoxib (Vioxx) after a study showed patients taking the drug on a long-term basis face twice the risk of a heart attack compared ...
Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to ...
Bethesda, MD (August 30, 2006) – The use of the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (Vioxx®) reduces the risk of colorectal adenomas, according to data being published in Gastroenterology, ...
Laboratory and case-control studies suggest a pivotal role for the cyclooxygenase-2 (COX-2) pathway in colorectal carcinogenesis. The purpose of this study was to test whether the COX-2 inhibitor ...
Clinical studies have failed to show convincing effects of nonsteroidal anti-inflammatory drugs (NSAIDs)—including the selective cyclo-oxygenase 2 (COX2) inhibitor rofecoxib—on the progression of ...
NEW YORK, June 27 (Praxis Press) Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) but it is unclear whether specific COX-2 inhibitors ...
Inhibition of cyclo-oxygenase 2 might slow the progression of colorectal cancer, but might also increase the risk of adverse cardiovascular events. The cyclo-oxygenase 2 inhibitor rofecoxib was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback